Showing 1751-1760 of 3038 results for "".
- Harrow Enters Into Agreement to Acquire Exclusive US Rights to Five Ophthalmic Products from Novartishttps://modernod.com/news/harrow-enters-into-agreement-to-acquire-exclusive-us-rights-to-five-ophthalmic-products-from-novartis/2481292/Harrow announced it has entered into a agreement for the acquisition of the exclusive US commercial rights to five FDA‑approved ophthalmic products from Novartis in a deal worth up to $175 million. This transaction, which is the second acquisition transaction between Har
- iSTAR Medical Expands Commercial Rollout of MINIject with First Surgeries in Sweden and Norwayhttps://modernod.com/news/istar-medical-expands-commercial-rollout-of-miniject-with-first-surgeries-in-sweden-and-norway/2481272/iSTAR Medical announced that the commercial rollout expansion for MINIject has continued with the first implantations performed in Sweden and Norway. MINIject is iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) implant and is currently the only commerciall
- BTIG to Host Ophthalmology Day on November 29, 2022https://modernod.com/news/btig-to-host-ophthalmology-day-on-november-29-2022/2481261/Global financial services firm BTIG announced that "Ophthalmology Day at BTIG" will take place on November 29, 2022. The virtual, 1-day event will include thematic panel discussions, one-on-one meetings and company presentations. The event will be hosted by:
- Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001 for Retinal Diseaseshttps://modernod.com/news/kinarus-receives-uspto-notice-of-allowance-for-lead-therapeutic-candidate-kin001-for-retinal-diseases/2481256/Kinarus Therapeutics announced the receipt of a Notice of Allowability from the United States Patent and Trademark Office (USPTO) for US Patent Application No. 16/500,504 “Methods of preventing or treating Ophthalmic Diseases" covering its therapeutic candidate KIN001 in age-relat
- Bloomberg: Novartis Considering Sale of Ophthalmology Unithttps://modernod.com/news/bloomberg-novartis-considering-sale-of-ophthalmology-unit/2481246/Novartis is considering selling its non-core assets, including its ophthalmology franchise, to raise money for cutting-edge medicines, according to a Bloomberg
- Nidek Launches the NT-1p Non-Contact Tono/Pachymeterhttps://modernod.com/news/nidek-launches-the-nt-1p-non-contact-tonopachymeter/2481241/Nidek announced the launch of the NT-1p Non-Contact Tono/Pachymeter. The NT-1p is an innovative device that fully automates reliable non-contact tonometry and pachymetry. By placing the chin on the chinrest, the NT-1p automatically detects the position of the eyes and begins measurement without p
- Medicontur Launches Bi-Flex Elon Nondiffractive EDOF IOLhttps://modernod.com/news/medicontur-launches-bi-flex-elon-nondiffractive-edof-iol/2481224/Medicontur announced the launch of the Bi-Flex Elon Nondiffractive EDOF IOL. The Elon, which was launched on September 6, features proprietary Wavefront Linking technology that is designed to create a true elongated focus with minimal optical disturbances. This non-d
- CooperVision Adds SynergEyes to Expand Specialty Contact Lens Adoption in North Americahttps://modernod.com/news/coopervision-adds-synergeyes-to-expand-specialty-contact-lens-adoption-in-north-america/2481220/Deepening its commitment to expand specialty contact lens adoption in North America and worldwide, CooperVision has added
- Novaliq Announces FDA Acceptance of the New Drug Application for CyclASol for the Treatment of Dry Eye Diseasehttps://modernod.com/news/novaliq-announces-fda-acceptance-of-the-new-drug-application-for-cyclasol-for-the-treatment-of-dry-eye-disease/2481186/Novaliq announced that the FDA has accepted the new drug application (NDA) for CyclASol (cyclosporine ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment for the signs and symptoms of dry eye disease (DED). The agency completed the filing revi
- Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 US and European Patentshttps://modernod.com/news/azura-ophthalmics-expands-broad-intellectual-property-portfolio-to-12-us-and-european-patents/2481182/Azura Ophthalmics announced the company’s US 11,459,351 patent (the ‘351 patent) was granted by the US Patent and Trademark Office. This patent strengthens the company’s extensive portfolio protecting its use of dual-action keratolytic drug conjugates in developme